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ABSTRACT (Word count: 248) 35 
Purpose: Lobular carcinoma in situ (LCIS) is a pre-invasive lesion of the breast. We sought to define 36 
its genomic landscape, whether intra-lesion genetic heterogeneity is present in LCIS, and the clonal 37 
relatedness between LCIS and invasive breast cancers. 38 
Experimental Design: We reanalyzed whole-exome sequencing (WES) data and performed a targeted 39 
amplicon sequencing validation of mutations identified in 43 LCIS and 27 synchronous more clinically-40 
advanced lesions from 24 patients (nine ductal carcinomas in situ (DCIS), 13 invasive lobular 41 
carcinomas (ILCs) and five invasive ductal carcinomas (IDCs)). Somatic genetic alterations, mutational 42 
signatures, clonal composition and phylogenetic trees were defined using validated computational 43 
methods. 44 
Results: WES of 43 LCIS lesions revealed a genomic profile similar to that previously reported for 45 
ILCs, with CDH1 mutations present in 81% of the lesions. Forty-two percent (18/43) of LCIS were found 46 
to be clonally-related to synchronous DCIS and/or ILCs, with clonal evolutionary patterns indicative of 47 
clonal selection and/or parallel/branched progression. Intra-lesion genetic heterogeneity was higher 48 
among LCIS clonally-related to DCIS/ILC than in those non-clonally related to DCIS/ILC. A shift from 49 
aging to APOBEC-related mutational processes was observed in the progression from LCIS to DCIS 50 
and/or ILC in a subset of cases. 51 
Conclusions: Our findings support the contention that LCIS has a repertoire of somatic genetic 52 
alterations similar to that of ILCs, and likely constitutes a non-obligate precursor of breast cancer. Intra-53 
lesion genetic heterogeneity is observed in LCIS and should be considered in studies aiming to develop 54 
biomarkers of progression from LCIS to more advanced lesions.  55 
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TRANSLATIONAL RELEVANCE (Word count: 127) 56 
We investigated the somatic genetic alterations affecting all protein coding genes in lobular carcinoma 57 
in situ (LCIS) and synchronously diagnosed ductal carcinomas in situ (DCIS) and invasive lobular (ILC) 58 
or ductal carcinomas (IDC). Our analyses revealed that LCIS is a genetically advanced lesion, often 59 
displaying intra-lesion genetic heterogeneity, with minor subclones of LCIS becoming the dominant 60 
clone in ILCs. An APOBEC-related mutational signature coupled with overexpression of APOBEC3B 61 
was found to be present in LCIS subclones progressing to more advanced lesions. Our findings support 62 
the notion that LCIS is a non-obligate precursor of ILC, and suggest that the development of robust 63 
molecular predictors of the risk of LCIS progression/evolution into more aggressive forms of breast 64 
cancer may benefit from the assessment of intra-lesion genetic heterogeneity in LCIS.  65 
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INTRODUCTION  66 
Lobular carcinoma in situ (LCIS) is a pre-invasive lesion of the breast, which is often multifocal and 67 
bilateral (1). Over the last three decades, LCIS has been clinically perceived as a risk indicator and 68 
managed accordingly (1). There is, however, burgeoning phenotypic and genetic evidence to suggest 69 
that LCIS is a non-obligate precursor of invasive breast cancer, akin to ductal carcinoma in situ (DCIS) 70 
(2). 71 
 72 
LCIS and invasive lobular carcinomas (ILCs) are phenotypically and genetically similar. Both lesions 73 
are preferentially of the luminal A molecular subtype (i.e. estrogen receptor (ER)-positive, HER2-74 
negative, low-grade and low-proliferation), and harbor recurrent gains of 1q and losses of 16q, 75 
encompassing the CDH1 gene locus, as well as recurrent CDH1 somatic mutations (1,3-7). In fact, loss 76 
of E-cadherin, the protein product of the CDH1 gene, is a hallmark feature of these lesions (3,6) and 77 
has been shown to result in the development of ILCs in conditional mouse models (8). Analyses of the 78 
genomic features of ILCs by The Cancer Genome Atlas consortium (TCGA) (6) and individual 79 
investigators (9) have revealed the genes most commonly mutated in this subtype of breast cancer, 80 
and identified molecular differences between invasive ductal carcinomas (IDCs) of no special type and 81 
ILCs, including a higher rate of FOXA1 mutations and a lower rate of GATA3 mutations in those with 82 
lobular histology. Additional whole-exome (WES) (7) and targeted (10) sequencing analyses focused 83 
on paired LCIS and ILCs demonstrated comparable rates of mutations affecting CDH1, PIK3CA and 84 
CBFB, among other genes.  85 
 86 
Previous studies have demonstrated that synchronous LCIS and invasive breast cancers may be 87 
clonally related and share a common ancestral lesion (4,7,10). In most studies, however, clonal 88 
relatedness was inferred using limited genomic information derived from copy number (4) or targeted 89 
sequencing analyses (10). By combining copy number and WES data, Begg et al. provided evidence of 90 
clonal relatedness between LCIS and associated lesions (7). These studies, however, did not 91 
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investigate the basis of the clonal relatedness between LCIS and ILC, and whether the progression 92 
from LCIS to ILC would involve the selection of specific subclones or happen through multiclonal 93 
invasion (11,12). Given that not only invasive breast cancers (13) but also pre-invasive lesions (11) 94 
may be genetically heterogeneous at diagnosis, and that tumor progression/stromal invasion may stem 95 
from clonal selection (11,13), it is plausible that LCIS may display intra-lesion genetic heterogeneity 96 
and that the progression from LCIS to more clinically advanced lesions, such as DCIS or invasive 97 
breast cancer, may result from the selection of pre-existing subclones.  98 
 99 
Here, we performed a re-analysis of WES data generated from a unique series of frozen LCIS samples 100 
from prospectively accrued, consecutive patients subjected to prophylactic or therapeutic mastectomy, 101 
previously published by Begg et al. (7). We performed a high-depth targeted capture sequencing 102 
validation of the mutations identified by WES in that study, using the same DNA samples and employed 103 
state-of-the-art bioinformatics algorithms with a Bayesian clustering model (PyClone) to infer subclone 104 
structure and with construction of clone based phylogeny, seeking to define the clonal composition and 105 
mutational processes in LCIS synchronously diagnosed with ILC, DCIS and/or IDC, and to ascertain 106 
whether changes in the clonal composition are observed in the progression from LCIS to DCIS or ILC. 107 
 108 
MATERIAL AND METHODS 109 
Subjects and samples 110 
This study is based on the 24 cases with available WES out of the 30 cases previously subjected to 111 
microarray-based comparative genomic hybridization and/or WES by Begg et al. (7). Eight out of the 24 112 
cases included in this study were also included in the targeted sequencing analysis previously reported 113 
by Sakr et al. (10). The cases subjected to WES include 43 LCIS and 27 synchronous more clinically-114 
advanced lesions (Table 1) (Supplementary Methods).  115 
 116 
Immunohistochemistry 117 
7 
 
Immunohistochemistry for ER, progesterone receptor (PR) and HER2 was performed essentially as 118 
previously described (11) (Supplementary Methods), and analyzed according to the American Society 119 
of Clinical Oncology (ASCO)/ College of American Pathologists (CAP) guidelines (14,15). 120 
 121 
Whole-exome sequencing data analysis 122 
Previously-generated (7) WES data from tumor-normal DNA samples were retrieved and re-analyzed. 123 
Neoplastic samples were sequenced to a median depth of 192x (range 95x-369x) and matched normal 124 
samples were sequenced to a median depth of 154x (range 105x-238x; Supplementary Table S1).  125 
 126 
WES data analysis was performed as described in Ng et al. (16) and detailed in the Supplementary 127 
Methods. In brief, after aligning the reads to the reference human genome GRCh37, somatic genetic 128 
alterations were detected using state-of the-art bioinformatics algorithms and filters were subsequently 129 
applied. In addition to the identification of single nucleotide variants (SNVs) and insertions and 130 
deletions (indels), for samples from a given patient, mutations that were identified in at least one 131 
sample were subsequently interrogated in all related samples (Supplementary Methods). Given that 132 
CDH1 germline mutations have been shown to be causative of familial gastric and breast cancer 133 
syndrome (17), the germline DNA samples from each patient were evaluated for the presence of 134 
pathogenic CDH1 germline mutations (Supplementary Methods). The potential functional effect of each 135 
somatic mutation was defined using a combination of mutation function predictors shown to have high 136 
negative predictive value (18), as previously described (19), and genes were annotated according to 137 
their presence in three cancer gene datasets, Kandoth et al. (20), the Cancer Gene Census (21) and 138 
Lawrence et al. (22). Allele-specific copy number alterations (CNAs) and loss of heterozygosity (LOH) 139 
for specific genes were defined using FACETS (23), as previously described (16), and purity and ploidy 140 
estimations were calculated using ABSOLUTE (24) (Supplementary Methods).  141 
 142 
Targeted amplicon re-sequencing validation of somatic mutations  143 
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A validation of the mutations found with WES was performed for cases with sufficient DNA material 144 
(n=11), using a custom designed AmpliSeq panel on an Ion Torrent Personal Genome Machine. This 145 
validation was not included in Begg et al. (7). Out of 4,061 somatic mutations identified by WES, 1,796 146 
were investigated in five LCIS, five DCIS, eight ILCs, and two IDCs from cases 1, 2, 4, 7, 8, 10, 11, 12, 147 
13, 14 and 15. 1,492 (83%) mutations were successfully validated. Mutations that had sufficient 148 
coverage in the validation experiment (minimum of 50 reads) but were not validated (allele frequency 149 
<1%) were excluded from the list of mutations used in the downstream analyses. 150 
 151 
Clonality analysis 152 
To infer the clonal relatedness between synchronous lesions, we defined the “clonality index” (CI) as 153 
the probability of two lesions sharing mutations not expected to have co-occurred by chance based on 154 
a previously validated method (25) (Supplementary Methods).  155 
 156 
Clonal frequencies 157 
To estimate the clonal architecture and composition of the lesions from each patient, mutant allelic 158 
fractions from all somatic mutations were adjusted for tumor cell content, ploidy, local copy number and 159 
sequencing errors using PyClone, as previously described (26) (Supplementary Methods). 160 
 161 
Truncal and branch mutations 162 
For each patient displaying at least one LCIS sample clonally-related to other lesions (LCIS, DCIS or 163 
ILC), we categorized the mutations into truncal and branch using PyClone (26) (Supplementary 164 
Methods). Truncal mutations were defined as those concurrently present in the modal populations of all 165 
LCIS and their clonally-related other lesions from a given patient. Branch mutations were defined as 166 
those comprising all non-truncal mutations. 167 
 168 
Measure of diversity 169 
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To quantitate the intra-lesion genetic heterogeneity of each sample analyzed, we used the Shannon 170 
diversity index (27) and Gini-Simpson index (28) (Supplementary Methods).  171 
 172 
Phylogenetic tree construction  173 
Maximum parsimony trees were built using binary presence/absence matrices built from the somatic 174 
genetic alterations, including synonymous and non-synonymous SNVs, indels and CNAs, within the 175 
clonally-related lesions from each patient, essentially as described by Murugaesu et al. (16,29) 176 
(Supplementary Methods). We have also employed Treeomics as an alternative approach for the 177 
reconstruction of phylogenetic trees (30). Treeomics reconstructs phylogenies using a Bayesian 178 
inference model and determines the probability that a variant is either present or absent in a given 179 
sample. 180 
 181 
Reverse transcription quantitative PCR (RT-qPCR) 182 
Total RNA was extracted using TRIZOL and reverse transcribed using SuperScript VILO Master Mix 183 
(Life Technologies, Thermo Fisher Scientific) according to the manufacturer’s instructions from cases 184 
for which sufficient frozen tissue samples were available. RT-qPCR was performed to analyze the 185 
expression levels of APOBEC3B, APOBEC3H and REV1 genes using TaqMan Assay-on-Demand 186 
(Supplementary Methods).  187 
 188 
Mutational frequencies of TCGA ILCs and luminal-A cancers 189 
TCGA luminal-A invasive breast cancers (31) and ILCs (6) and their mutations were retrieved from the 190 
"Final Full BRCA Sample Summary" and "Mutations - Publicly accessible MAF archives" at https://tcga-191 
data.nci.nih.gov/docs/publications/brca_2012/ and https://tcga-192 
data.nci.nih.gov/docs/publications/brca_2015/, including all non-silent, non-RNA mutations for 209 193 
luminal-A primary invasive breast cancers and 127 ILCs. Previous studies have demonstrated the 194 
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equivalence between the TCGA pipeline and the pipeline employed in this study for mutation detection 195 
(19,32). 196 
 197 
Mutational signatures 198 
To define the mutational signatures involved in the development of LCIS, DCIS and ILCs, we employed 199 
deconstructSigs (33) based on the set of mutational signatures “signature.cosmic” (34). 200 
 201 
Statistical analysis 202 
Analyses were performed using R. For comparisons between categorical variables, the Fisher’s exact 203 
test was employed, whereas for continuous variables, the Student’s t-test and Mann–Whitney U test 204 
were employed as appropriate. A hypergeometric test was performed to estimate the statistical 205 
significance of the enrichment for cancer genes (genes present in at least one of the cancer gene lists 206 
by Lawrence et al. (Cancer 5000-S) (22), Kandoth et al. (20) and/or Cancer Gene Census (21); n=745) 207 
in the genes with truncal mutations (n=559) and branch mutations (n=2,452). For the hypergeometric 208 
test, the total number of genes in the genome used was 18,986, as defined as the number of protein-209 
coding genes by the HUGO Gene Nomenclature Committee. The representation (enrichment) factors 210 
and the P-values of the hypergeometric tests were provided for the analyses performed. All tests were 211 
two-sided and P-values<0.05 were considered statistically significant, adjusted for multiple 212 
comparisons where specified.  213 
 214 
RESULTS  215 
LCIS displays a repertoire of somatic genetic alterations consistent with those of ILCs and 216 
luminal A-like breast cancers 217 
This study consists of a re-analysis of previously described WES data (7), followed by a previously 218 
unpublished targeted amplicon sequencing validation of approximately 1,800 selected mutations, from 219 
43 LCIS and synchronous DCIS (n=9), ILCs (n=13) or IDCs (n=5) from 24 patients (Table 1). Three 220 
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patients underwent bilateral mastectomy, one was therapeutic for bilateral breast cancer and two 221 
patients underwent contralateral prophylactic mastectomy; these three patients were found to have 222 
bilateral LCIS (Table 1). All LCIS lesions were of classic type and all DCIS were of intermediate nuclear 223 
grade. For those patients with invasive lesions, tumor size and ER, PR and HER2 status in invasive 224 
tumor cells are described in Table 1. Notably, all invasive carcinomas were ER-positive/HER2-225 
negative. 226 
 227 
Somatic mutation analysis of the 43 LCIS lesions revealed a median of 20 non-synonymous somatic 228 
mutations/lesion (range 5-333) and a mutation rate of 0.39 mutations/Mb (Figs. 1A and 2A-D), 229 
comparable to the number of non-synonymous somatic mutations and the mutation rates of 209 230 
luminal-A invasive breast cancers (31) and 127 ILCs (6) from TCGA (i.e. 27 somatic mutations/lesion 231 
(range 7-203) and 0.52 mutations/Mb in luminal-A and 29 somatic mutations/lesion (range 1-1,080) and 232 
0.56 mutations/Mb in ILCs; Mann–Whitney U test, P>0.1). Consistent with the notion that CDH1 233 
inactivation is a driver of lesions with lobular histologic features (1), we observed pathogenic mutations 234 
affecting the CDH1 gene in 35 of 43 (81%) LCIS, of which all but three were somatic; patient 13, who 235 
had three distinct foci of LCIS, was found to harbor a CDH1 germline mutation. All but two CDH1 236 
mutations were coupled with loss of heterozygosity (LOH) of the wild-type allele (77% (33/43) of all 237 
LCIS analyzed, Fig. 1A). Moreover, all LCIS cases lacked E-cadherin expression by 238 
immunohistochemical analysis. LCIS lacking CDH1 mutations did not harbor mutations or deletions 239 
affecting genes coding for additional proteins that comprise the cadherin-catenin complex, such as 240 
CTNNB1 (β-catenin), CTNNA1 (α-catenin) or CTNND1 (p120-catenin), nor somatic or germline genetic 241 
alterations in RHOA (Supplementary Data File 1), a gene that has been implicated in the biology of 242 
gastric cancer (35), and whose alterations result in neoplastic cells displaying discohesiveness akin to 243 
that caused by CDH1 loss of function.  244 
 245 
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Additional genes identified by TCGA to be significantly mutated in ILCs (6), such as PIK3CA, TBX3, 246 
FOXA1 and MAP3K1, were also found to be recurrently somatically mutated in LCIS (Figs. 1A and 247 
2E); however, TP53 somatic mutations, and PTEN somatic mutations and homozygous deletions, 248 
present in 8%, 7%, and 6% of ILCs analyzed by TCGA (6), were not found in any of the LCIS analyzed 249 
here. Notably, TP53 mutations were significantly more frequently found in luminal A invasive breast 250 
cancers from TCGA than in the LCIS analyzed here (12% (25/209) vs 0% (0/43), Fisher’s exact test, 251 
P=0.019, Fig. 2E). Moreover, genes identified by TCGA to be significantly mutated in luminal A 252 
invasive breast cancers, including CBFB, GATA3, NCOR1 and MED23 were also found be recurrently 253 
mutated in LCIS. Interestingly, however, CBFB was found to be mutated in 19% (8/43) of LCIS, a rate 254 
significantly higher than that in 2% (2/127) of ILCs and 2% (5/209) of luminal-A breast cancers from 255 
TCGA (Fisher’s exact tests, P<0.01, Fig. 2E). Gene CNA analysis revealed recurrent losses of 16q and 256 
gains of 1q (Fig. 1B), a pattern also observed in ILCs (4,6) and luminal-A invasive breast cancers (31). 257 
Taken together, our findings demonstrate that LCIS synchronously diagnosed with more advanced 258 
lesions in this study is a genetically-advanced, neoplastic lesion often driven by E-cadherin loss of 259 
function, with a spectrum of somatic genetic alterations affecting genes commonly altered in ILCs and 260 
luminal-A invasive breast cancers. 261 
 262 
LCIS is often clonally-related to DCIS and ILCs 263 
WES of nine DCIS (a non-invasive precursor lesion perceived clinically to be more advanced than LCIS 264 
(36,37)), 13 ILCs, and five IDCs collected synchronously with the LCIS analyzed above demonstrated 265 
that overall these lesions displayed similar number of mutations/case, mutation rates, repertoires of 266 
CNAs and non-synonymous somatic mutations to those of the LCIS analyzed in this study (Fig. 1, 2A-267 
D), with exception of CDH1 somatic mutations that were exclusively found in LCIS and ILCs. 268 
 269 
We reasoned that the somatic mutations and CNAs found in anatomically distinct foci of LCIS, ILC, 270 
DCIS and IDC could provide a basis for defining their clonal relatedness. Consistent with the analysis 271 
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reported by Begg et al. (7), but based on distinct bioinformatics and biostatistical approaches 272 
(Supplementary Methods), here we demonstrate that all multifocal LCIS originating in the same breast 273 
quadrant (8/8 samples, four patients; cases 4, 7, 9, 23) were clonally-related, harboring several 274 
identical somatic mutations and CNAs (Fig. 3A, Supplementary Figs. S1-S3). Sixty-seven percent 275 
(16/24) of multifocal LCIS affecting distinct quadrants of the breast were also clonally-related (Fig. 3A). 276 
Further, 10/13 (77%) ILCs and 5/9 (56%) DCIS samples were found to be clonally-related to at least 277 
one synchronous LCIS analyzed (Fig. 3A). Interestingly, none of the five IDCs studied were found to be 278 
clonally-related to a LCIS (Fig. 3A), however, in all three cases where synchronous DCIS and IDC 279 
samples were analyzed, the DCIS and IDC were found to be clonally-related (Fig. 3A, Supplementary 280 
Figs. S1-S2). As expected, no clonal relatedness was observed between lesions arising in distinct 281 
breasts (bilateral cases; Fig. 3A, Supplementary Figs. S1-S2). In addition, the clonal relatedness 282 
reported by Sakr et al. for the 8 pairs of LCIS and ILC were confirmed in this study (Supplementary 283 
Table S2). 284 
 285 
Taken together, our findings indicate that the majority of multifocal LCIS lesions are clonally-related, 286 
and that the presence of these lesions in distinct quadrants of the breast does not predict their clonal 287 
relatedness. LCIS and synchronous DCIS and/or ILC are often clonally-related, corroborating the notion 288 
(4,7,38,39) that LCIS is a non-obligate precursor of more clinically-advanced lesions, in particular ILCs. 289 
Furthermore, no evidence of clonality between LCIS and IDC was observed here, suggesting that direct 290 
progression from CDH1-mutant LCIS to IDC is an uncommon biological phenomenon. 291 
 292 
LCIS foci displaying intra-lesion genetic heterogeneity are more likely to progress to ILCs 293 
Recent studies have demonstrated that intra-tumor genetic heterogeneity may be present in non-294 
invasive lesions including DCIS (11,40) and pre-invasive lesions arising in other organs (e.g. of the 295 
esophagus)(41). In such cases, all neoplastic cells harbor the founder genetic events (i.e. truncal 296 
mutations) and subclonal populations of cancer cells display additional genetic alterations (i.e. branch 297 
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mutations)(42). We posited that LCIS would harbor intra-lesion genetic heterogeneity and that LCIS 298 
lesions when clonally-related to DCIS or ILC would be associated with a higher level of intra-lesion 299 
genetic heterogeneity than LCIS not clonally-related to more advanced lesions.  300 
 301 
To test this hypothesis, we resolved the clonal composition of LCIS, DCIS and/or ILC samples by 302 
applying a Bayesian clustering model (PyClone (26)) to mutant allele fractions, incorporating tumor 303 
cellularity, ploidy and local copy number obtained from ABSOLUTE (24) and/or FACETS (23) 304 
(Supplementary Methods). This analysis revealed that all but two (89%; 16/18) LCIS clonally-related to 305 
DCIS/ILC but only 40% (10/25) of LCIS not clonally-related to DCIS/ILC displayed intra-lesion genetic 306 
heterogeneity at the sequencing depth analyzed (Fisher’s exact test, P=0.0016, Supplementary Figs. 307 
S4A-B). These findings were further corroborated by an analysis of the Shannon and Gini-Simpson 308 
diversity indices (27,28,43), which demonstrated that as a group LCIS clonally-related to DCIS and/or 309 
ILC (n=18) displayed significantly higher intra-lesion genetic heterogeneity than LCIS not clonally-310 
related to more advanced lesions (n=25) (Mann–Whitney U test, P=0.005, Fig. 3B-C, Supplementary 311 
Figs. S4C-D). Interestingly, in case 4, composed of two LCIS and one ILC, all sharing a common 312 
ancestor, the LCIS lesion displaying heterogeneity was found to be the likeliest direct precursor of the 313 
ILC (Fig. 4A).  314 
 315 
Given the intra-lesion genetic heterogeneity observed in LCIS, in particular in those related to more 316 
advanced lesions, we sought to define whether the branch mutations found in these lesions would 317 
affect ‘passenger’ genes or genes significantly mutated in cancer (20-22). Contrary to the notion that 318 
heterogeneity would primarily affect passenger genetic events, both truncal and branch non-319 
synonymous somatic mutations detected in LCIS clonally-related to the other lesions were found to 320 
target genes significantly enriched for known cancer drivers (20-22) (hypergeometric test, 321 
representation factor=2.09, P<0.01, and hypergeometric test, representation factor=1.5, P<0.01, 322 
respectively; Supplementary Figs. S4E-F). Importantly, however, in agreement with previous multi-323 
15 
 
region analyses that suggested that most of the driver genetic alterations are early truncal events 324 
(13,16,44), the enrichment for cancer genes was higher in the constellation of truncal than in branch 325 
mutations. Truncal mutations included genes found to be significantly mutated in ILCs and/or luminal-A 326 
invasive breast cancers, including CDH1, PIK3CA, MAP3K1, CBFB, SF3B1, RUNX1 and FOXA1 327 
(Supplementary Data File 1), whereas branch mutations included GATA3, PIK3CA, ERBB2 and 328 
KMT2C.  329 
 330 
Given the clonal relatedness of LCIS with DCIS and ILC, we posited that progression from LCIS to 331 
DCIS/ILC could result in the selection of specific subclones harboring private genetic alterations 332 
(11,12,40). In 29% (4/14) of cases where LCIS was clonally-related to DCIS or ILC, we observed that a 333 
selected population from the LCIS became dominant in the respective DCIS or ILC (Fig. 4, 334 
Supplementary Fig. S1), whereas in the remaining 10 cases our findings suggested parallel 335 
progression between LCIS, DCIS and/or ILC. In two cases (cases 4 and 10), a minor subclone from a 336 
LCIS was the likeliest substrate for the development of the DCIS or the ILC (Fig. 4). In cases 1, 11 and 337 
16, the biological chronology of the LCIS and DCIS could not be resolved on the basis of the 338 
sequencing data available (Supplementary Fig. S1). Analysis of the genes affected by branch somatic 339 
mutations restricted to, or enriched in, the DCIS/ILC samples clonally-related to LCIS revealed that in 340 
the progression from LCIS to DCIS or ILC, known cancer driver genes were affected by somatic 341 
mutations (e.g. MAP3K1 (2 cases), RUNX1, NCOR1, ARID1A and TBX3 (2 cases)) or LOH of the wild-342 
type allele (Figs. 1 and Supplementary Fig. S4F, Supplementary Data File 1).   343 
 344 
Taken together, our results demonstrate that LCIS clonally-related to DCIS/ILC more frequently 345 
displays intra-lesion genetic heterogeneity than LCIS not clonally-related to more advanced lesions, 346 
that both truncal and branch mutations are enriched for known cancer drivers, and that known cancer 347 
genes are likely targeted by somatic genetic events in the progression from LCIS to more clinically 348 
advanced lesions. 349 
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 350 
Shifts in mutational processes are linked to progression from LCIS to DCIS and ILCs 351 
There is evidence to suggest that the mutational processes that shape the mutational spectra of tumors 352 
may change during evolution (16,45). Hence, we sought to define whether changes in mutational 353 
spectra were observed in the transition from LCIS to DCIS/ILC. Given that truncal mutations are likely 354 
reflective of biological phenomena that took place prior to or during the development of LCIS, and that 355 
branch mutations in DCIS/ILC likely stem from mutational processes involved in tumor maintenance 356 
and progression, we compared the mutational spectrum of truncal and branch mutations in cases 357 
where LCIS was clonally-related to DCIS/ILC. Both truncal and branch mutations were found to be 358 
enriched for C>T transitions in the NpCpG context, consistent with a signature ascribed to aging (46), 359 
and C>G transversions and C>T transitions in the TpCpW context, suggestive of the mutational 360 
processes caused by APOBEC DNA cytosine deaminase activity (47); the latter being predominately 361 
found in the branch mutations of case 4 (Fig. 5A) and emerging in the DCIS of case 1 and ILC of case 362 
18 (Fig. 5B-C). Akin to the variations in mutational processes observed in the progression of other 363 
cancer types (29,45), in-depth analysis of cases 1, 4 and 18 revealed that a mutational process 364 
consistent with the APOBEC signature was active in the progression from LCIS to DCIS or ILC (Fig. 5). 365 
Moreover, the mRNA levels of APOBEC3B, a DNA cytosine deaminase that has been causally 366 
implicated in the development of APOBEC signature mutations in cancer (47,48), were significantly 367 
higher in samples displaying an APOBEC mutational process than in those displaying an aging 368 
signature (Fig. 5D). These observations combined to indicate that, at least in a subset of cases, the 369 
APOBEC mutational process is likely to be contributing to the development of more advanced lesions.  370 
 371 
DISCUSSION 372 
Here we provide direct evidence of the neoplastic and non-obligate precursor nature of at least a 373 
subset of LCIS. By performing a clonal decomposition and clonal relatedness analysis of LCIS and 374 
synchronously diagnosed DCIS, ILCs and/or DCIS, we have observed that LCIS can display intra-375 
17 
 
lesion genetic heterogeneity and be clonally-related to DCIS and ILCs, whereas progression from LCIS 376 
to IDC is likely a rare event. Notably, LCIS clonally related to ILCs and/or DCIS were found to display 377 
higher levels of intra-lesion genetic heterogeneity than LCIS that were not clonally related to a more 378 
advanced lesion, and evidence of clonal selection in the progression from LCIS to ILCs and/or DCIS 379 
was documented in a subset of patients. In these patients, the APOBEC mutational process, which has 380 
been implicated in genetic instability and intra-tumor genetic heterogeneity, appears to be present later 381 
in the evolution of LCIS and may be involved in its progression to more advanced lesions. Interestingly, 382 
the samples enriched for APOBEC mutation process displayed higher expression levels of 383 
APOBEC3B, whose activity has been shown to be mutagenic (47). Therefore, one hypothesize that in a 384 
subset of LCIS, upregulation of APOBEC3B results in increased mutagenesis and intra-tumor genetic 385 
heterogeneity, ultimately promoting subclonal expansions and progression to ILC. 386 
 387 
LCIS has been historically considered a less advanced lesion as compared to DCIS, and is usually 388 
managed conservatively, not mandating surgical excision (1). Accordingly, in the latest version of the 389 
TNM staging system, LCIS is no longer staged as an in situ carcinoma (pTis) as DCIS is (49). It should 390 
be noted that although we detected clonal relatedness between LCIS and DCIS, and the LCIS as the 391 
potential substrate for the development of the DCIS (i.e. case 10), the directionality of the evolution was 392 
not clear in three cases (i.e. cases 1, 11 and 16). Hence, we cannot rule out the possibility that in a 393 
subset of cases, LCIS may have arisen from a preexistent DCIS or a common precursor (e.g. flat 394 
epithelial atypia). In fact, due to the molecular similarities between low-grade LCIS and DCIS (2), 395 
inactivation of CDH1 in a DCIS subclone would be the likeliest explanation for such a phenotypic shift. 396 
Bi-directional progression between lesions of lobular (atypical lobular hyperplasia and LCIS) and ductal 397 
phenotype (atypical ductal hyperplasia and DCIS) is entirely consistent with the proposed concept of a 398 
low nuclear grade breast neoplasia family (2), which encompasses a group of low-grade, ER-positive 399 
neoplasms of the breast that not uncommonly affect the same segment of the breast, if not the same 400 
terminal ductal-lobular unit, and share a remarkably similar genomic landscape, having concurrent 1q 401 
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gains and 16q losses, and PIK3CA mutations, as their genetic signature (2). Alternatively, both LCIS 402 
and DCIS might arise from a common precursor (i.e. case 1), such as flat epithelial atypia (2). Taken 403 
together, these findings support the notion that the progression of LCIS and DCIS might be 404 
bidirectional, or that these lesions may evolve in parallel from a common ancestor.  405 
 406 
Our findings demonstrate that LCIS displays a genomic landscape comparable to that of invasive 407 
breast cancers of luminal A subtype (31) and/or of lobular histology (6), lesions unequivocally more 408 
advanced and that mandate therapeutic intervention. Akin to ILCs (6), LCIS harbors recurrent bi-allelic 409 
inactivation of CDH1 (77%), and recurrent mutations affecting genes commonly mutated in breast 410 
cancer, including PIK3CA, FOXA1 and TBX3, among other genes. It should be noted, however, that 411 
genetic alterations affecting TP53 and PTEN, previously found as recurrent events in ILCs (6), were not 412 
identified in the LCIS samples analyzed in this study. These differences might be related to the fact that 413 
our cohort included only classic LCIS, but given that progression may occur via clonal selection, and 414 
that not only truncal, but also branch mutations are enriched for known cancer genes, it is plausible that 415 
acquisition of genetic alterations, including those resulting in inactivation of these two bona fide tumor 416 
suppressor genes, may play a role in the progression to ILC. Indeed, we (7,11) and others (13) have 417 
demonstrated previously that loss of PTEN may be associated in the progression from DCIS to IDC.  418 
 419 
The finding that LCIS is unlikely clonally-related to IDCs is in contrast with previous publications, 420 
including that from Begg et al. (7), who reported two LCIS lesions clonally-related to IDCs based on a 421 
limited number of shared mutations (one and three mutations in Patients 9 and 14, respectively), which 422 
is substantially lower than the number of shared mutations observed in clonally-related LCIS-ILC or 423 
LCIS-DCIS lesions in this study (median 12, range 2-171). The mutations described by Begg et al. (7) 424 
found to be shared between LCIS and IDC samples may have constituted sequencing artifacts, 425 
germline mutations or common single nucleotide polymorphisms (SNPs) (Supplementary Table S2, 426 
Supplementary Data File 1), as they were filtered out in our more conservative somatic mutation 427 
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analysis. Although we did not detect direct clonal relatedness between LCIS and IDC in this study, we 428 
cannot rule out the possibility that a subset of synchronous IDC and LCIS may share a common early 429 
precursor or that ductal lesions and LCIS may arise from a common earlier precursor lesion and 430 
undergo parallel evolution. In addition, it is also plausible that a subset of LCIS may stem from DCIS 431 
harboring 16q losses, but the CDH1 inactivation takes place later in the evolution of the lesion.  432 
 433 
Although our findings define LCIS as a non-obligate precursor of ILC, they do not imply that changes in 434 
the clinical management of patients presenting with LCIS are necessary, as the rate of subsequent 435 
breast cancer development in a large cohort of patients with a diagnosis of LCIS as reported by the 436 
SEER database demonstrates a risk of approximately 1% per year (50). Nonetheless, our study might 437 
provide a framework for the identification of markers to define LCIS cases that have a greater likelihood 438 
to progress. Although some of the pathologic characteristics of LCIS, such as volume of disease, are 439 
associated with a greater likelihood of progression to DCIS/ILC, there has yet to be a validated 440 
biomarker to predict the behavior of classic LCIS. Based on our results, one could posit that assessing 441 
the levels of intra-lesion genetic heterogeneity and/or APOBEC3B activity in LCIS may help select 442 
patients that should be counseled more proactively towards surgical excision and/or hormonal 443 
chemoprevention, akin to the current management of low- to intermediate-grade DCIS. Increasingly, 444 
treatment of early ER-positive breast cancer relies on pathologic features, tumor burden and genomic 445 
profiles; our findings suggest that with continued investigation a combination of clinical features, 446 
histologic classification, assessment of volume of disease and intra-lesion genetic heterogeneity may 447 
allow a more personalized risk assessment for patients with LCIS. 448 
 449 
Our study has important limitations. The prospective accrual of frozen samples of LCIS adequate for 450 
detailed molecular studies is remarkably challenging; hence the sample size of the present study is 451 
small. In addition, our study may not be representative of incidental cases of LCIS, given that the 452 
patients included in this study were accrued in a prospective protocol for the multiregional sampling of 453 
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prophylactic and/or therapeutic mastectomies from patients with a previous diagnosis of LCIS. 454 
Moreover, we only performed WES analysis, hence we cannot rule out that non-coding alterations 455 
and/or epigenetic changes may play a role in the development and progression of LCIS. More 456 
comprehensive analyses may also be required to define the alternative drivers of CDH1 wild-type LCIS. 457 
Finally, we used tumor bulk sequencing and state-of-the-art computational approaches to infer the 458 
clones present in each sample/case and their phylogeny. Single-cell sequencing analyses of LCIS and 459 
synchronous lesions are warranted to confirm our findings and provide direct evidence of the clonal 460 
composition of LCIS and of clonal selection in the evolution to more advanced lesions. 461 
 462 
Despite these limitations, this proof-of-principle study demonstrates that LCIS is a neoplastic non-463 
obligate precursor of DCIS and ILC, with a repertoire of somatic genetic alterations similar to that of 464 
ILCs and luminal-A invasive breast cancers, but lacking TP53 and PTEN mutations. LCIS at diagnosis 465 
often displays intra-lesion genetic heterogeneity, and, in a subset of cases, the progression from LCIS 466 
to DCIS and ILC may involve the selection of clones, which may harbor distinct active mutational 467 
processes such as APOBEC. Our findings suggest that early documentation of intra-lesion genetic 468 
heterogeneity may be central to developing robust molecular predictors of the risk of LCIS 469 
progression/evolution into more aggressive forms of breast cancer. 470 
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TABLE 1: Clinico-pathologic characteristics of the 24 patients included in the study. 
Case 
ID 
Breast 
laterality 
Frozen 
tissue                     
blocks 
analyzed 
(n) 
Type Tumor 
size 
(invasive, 
mm) 
Lymph 
node 
status 
ER  
 
PR  
 
HER2 
 
Sakr 
et al. 
Begg 
et al. LCIS
* 
DCIS
** 
ILC IDC 
1 Left 16 ✔ ✔     N/A N/A + + + N Y 
2 Right 81 ✔   ✔   21 + + + - Y Y 
3 Left 52 ✔ ✔   ✔ 18 - + + - N Y 
4 Right 28 ✔   ✔   28 - + - - Y Y 
5 Left 27 ✔   ✔   23 - + + - N Y 
6 Left 28 ✔   ✔   16 + + + - N Y 
7 Left 27 ✔ ✔ ✔ ✔ 15 - + + - N Y 
8 Left 26 ✔   ✔   60 + + + - Y Y 
9 Right 54 ✔     ✔ 37 + + + - Y Y 
10 Left 24 ✔ ✔     N/A N/A + + - N Y 
11 Right 97 ✔ ✔ ✔   14 + + + - N Y 
12 Right 52 ✔   ✔   30 + + + - N Y 
13 
Left 
50 
✔       N/A N/A + + - N Y 
Right ✔   ✔   17 - + + - N Y 
14 
Left 
50 
✔       N/A N/A + + - N Y 
Right ✔     ✔ 7.5 - + + - N Y 
15 
Left 
50 
✔ ✔   ✔ 18 + + + - N Y 
Right ✔   ✔   35 + + + - N Y 
16 Left  N/A ✔ ✔     N/A N/A + + - N Y 
17 Left  N/A  ✔       N/A N/A + + - N Y 
18 Left N/A ✔   ✔   16 N/A + + - Y Y 
19 Left  N/A  ✔ ✔     N/A N/A + + - N Y 
20 Left  N/A  ✔       N/A N/A + + - N Y 
21 Left N/A ✔       N/A N/A + + - N Y 
22 Right  N/A  ✔   ✔   21 N/A + + - Y Y 
23 Right  N/A  ✔       N/A N/A + + - Y Y 
24 Right  N/A  ✔   ✔   13 N/A + + - Y Y 
 
DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma of no special type; ILC, invasive lobular 
carcinoma; LCIS, lobular carcinoma in situ; ER, estrogen receptor; PR, progesterone receptor; HER2, 
epidermal growth factor receptor 2; +, positive; -, negative; N/A, not available; *all LCIS are of classic 
type; **all DCIS are of grade 2; Y, the case was analyzed in the previous study; N, the case was not 
analyzed in the previous study. 
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FIGURE LEGENDS 
Fig. 1: Landscape of somatic genetic alterations of lobular carcinoma in situ (LCIS) and 
associated lesions.  
A) Heatmap illustrating the recurrent (n≥2) somatic mutations and selected gene amplifications in LCIS 
(n=43), invasive lobular carcinomas (ILCs, n=13), ductal carcinoma in situ (DCIS, n=9) and invasive 
ductal carcinomas (IDC, n=5), subjected to whole-exome sequencing. Cases are shown in columns, 
grouped according to histologic category color-coded according to the legend, and genes in rows. 
Somatic mutations affecting cancer genes listed in Kandoth et al. (20), the Cancer Gene Census (21) 
and/or Lawrence et al. (22) are ordered from top to bottom in decreasing order of frequency, followed 
by selected gene amplifications. Genes highlighted in bold and/or red represent significantly mutated 
genes in ILCs and/or luminal-A invasive breast cancers from The Cancer Genome Atlas breast cancer 
studies (6,31). B) Heatmap illustrating the copy number alterations found in LCIS (n=43), ILC (n=13), 
DCIS (n=9) and IDC (n=5). For A and B, mutation type, copy number states, and/or type of lesion are 
indicated according to the color keys on the right of the figure. Indel, insertion and deletion; SNV, single 
nucleotide variant.  
 
Fig. 2: Comparison of mutation rate and frequency of mutations at gene level affecting lobular 
carcinoma in situ (LCIS) and invasive lobular carcinomas (ILCs) and Luminal A breast cancers 
from The Cancer Genome Atlas (TCGA) breast cancer study. 
A and B) Boxplots showing the mutation burden and C and D) mutation rate (Mutation/Mb) in LCIS 
samples (n=43) and ILC (n=13), DCIS (n=9) and IDC (n=5) from this study and ILC (n=127) and 
Lumina A tumors (n=209) from TCGA (31). NS: not significant *p-value>0.05, **p-value>0.1 (Mann–
Whitney U test). E) Heatmap depicting the most recurrently mutated genes affecting cancer genes 
identified in LCIS samples from this study and ILCs (6) and luminal A invasive breast cancers (31) from 
TCGA. Cases are shown in columns, genes in rows. Fisher's exact test comparisons of mutational 
frequencies of the mutated genes were performed between LCIS from this study (n=43) and 127 ILCs 
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(6) and 209 Luminal A breast cancers (31) from TCGA. The significantly different mutation frequencies 
between LCIS and TCGA ILCs and/or luminal A breast cancers (TCGA) are highlighted with an 
asterisk, where **p-value < 0.01 and *p-value < 0.05 (Fisher’s exact test). 
 
Fig. 3: Clonal relatedness and intra-lesion genetic heterogeneity in lobular carcinoma in situ 
(LCIS), invasive lobular carcinoma (ILC), ductal carcinoma in situ (DCIS). 
A) Schematic representation of the anatomical locations (breast quadrants) of all sequenced samples 
in each patient and their clonal relatedness. Clonally-related lesions are connected by orange or green 
lines, while those in black represent lesions without a clonal relationship with any other lesion from the 
respective patient. In cases of unilateral LCIS, only the left or right breast was represented, and in 
cases of bilateral LCIS, both breasts were schematically depicted. Boxplot illustrating the distribution of 
B) the Shannon diversity index and C) the Gini-Simpson diversity index in LCIS not clonally-related to 
DCIS/ILC (n=25) and in LCIS clonally-related to DCIS and/or ILC (n=18). The colored dots indicate the 
cases. P-values of unpaired t-test with Welch’s correction are indicated at the top of each figure. NS: 
not significant, p-value >0.05. 
 
Fig. 4: Clonal composition of clonally-related lobular carcinoma in situ (LCIS) and ductal 
carcinoma in situ (DCIS) or invasive lobular carcinoma (ILC) and potential clonal selection 
during progression.  
A and B) Decomposition of genetically distinct clones and clonal evolution in lesions from A) case 4 
and B) case 10 using the results from PyClone (26). On the top left, a schematic representation of the 
quadrants from which each sequenced lesion was sampled is shown, and on the top right, the clonal 
frequency heatmap of mutations within the lesions of each case, grouped by their inferred clonal/ 
subclonal structure (clusters). Non-synonymous somatic mutations are shown. The clusters inferred by 
PyClone are shown below the clonal frequency heatmap, and the Shannon index measuring intra-
lesion genetic heterogeneity for each lesion is specified within parentheses after the sample names in 
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the heatmap. On the bottom left, the parallel coordinates plot generated by PyClone and, in the middle 
right, a cluster-based phylogenetic tree based on the clusters identified by PyClone are shown. The 
color of the trunk and branches matches the color of their respective clusters shown in the parallel 
corrdinates plot. On the bottom right, a histologic lesion-based phylogenetic tree constructed using 
Treeomics (30) is depicted. The mutations affecting cancer genes (colored in orange) and the hotspot 
mutations (colored in red) that define a given clone are illustrated alongside the branches. The length of 
the branches is proportional to the number of mutations that distinguish a given clone from its ancestor. 
The numbers alongside the branches represent the total number of somatic mutations. 
 
Fig. 5: Mutational signatures of trunk and branch mutations in lobular carcinoma in situ (LCIS) 
clonally-related ductal carcinoma in situ (DCIS) or invasive lobular carcinoma (ILC). 
Evolution of the mutational processes with a schematic representation of the subclone structure in A) 
case 4, B) case 1 and C) case 18. Each black line represents the acquisition of somatic genetic 
alterations that define a given clone and each arrow depicts the divergence of a cell population from 
one lesion to another along with the acquisition of a set of somatic genetic alterations. The mutational 
signature representative of newly acquired mutations by a given subclone is depicted adjacent to each 
circle. The pie chart depicts the proportion of mutational signatures detected and signature 1 (aging, 
blue), signature 2 (APOBEC, violet) and signature 13 (APOBEC, green) are shown, with the remaining 
mutational signatures merged as ‘Others’ (dark gray). The number alongside the branches is the total 
number of somatic mutations. D) Reverse transcription quantitative PCR (RT-qPCR) of APOBEC3B 
(left), APOBEC3H (middle) and REV1 (right) genes in samples displaying the APOBEC-related and 
aging-related signatures, where tissue samples were available for RNA extraction. The error bars 
represent the standard deviation of mean of RT-qPCR data (n=3). 
 





